Surgeon meets challenges of performing gene therapy

Audina Berrocal
On March 22, a Florida boy underwent gene therapy with Luxturna for treatment of inherited retinal disease at the Bascom Palmer Eye Institute, a first for the institution.
“Of course there were challenges,” the boy’s surgeon, Audina M. Berrocal, MD, told
Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics) was FDA approved in December 2017 for individuals with biallelic RPE65 mutation-associated retinal dystrophy, and the first treatment was done March 20 at Massachusetts Eye and Ear.
Creed Pettit, a 9-year-old from Mount Dora, Florida, was

Full Story →